1.Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B: Association of oral calcitriol with improved survival in nondialyzed CKD. Journal of the American Society of Nephrology: JASN 2008, 19(8):1613–1619.
2.Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K: Association of activated vitamin D treatment and mortality in chronic kidney disease. Archives of internal medicine 2008, 168(4):397–403.
3.Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T et al: Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 2004, 19(1):179–184.
4.Sugiura S, Inaguma D, Kitagawa A, Murata M, Kamimura Y, Sendo S, Hamaguchi K, Nagaya H, Tatematsu M, Kurata K et al: Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. Clinical and experimental nephrology 2010, 14(1):43–50.
5.Duranton F, Rodriguez-Ortiz ME, Duny Y, Rodriguez M, Daures JP, Argiles A: Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. American journal of nephrology 2013, 37(3):239–248.
6.Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. The Journal of clinical investigation 2002, 110(2):229–238.
7.Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D: Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney international 2008, 74(2):170–179.
8.Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE et al: Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(43):16810–16815.
9.Chen S, Law CS, Grigsby CL, Olsen K, Hong TT, Zhang Y, Yeghiazarians Y, Gardner DG: Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation 2011, 124(17):1838–1847.
10.Al-Sofiani ME, Jammah A, Racz M, Khawaja RA, Hasanato R, El-Fawal HA, Mousa SA, Mason DL: Effect of Vitamin D Supplementation on Glucose Control and Inflammatory Response in Type II Diabetes: A Double Blind, Randomized Clinical Trial. International journal of endocrinology and metabolism 2015, 13(1):e22604.
11.Sassi F, Tamone C, D’Amelio P: Vitamin D: Nutrient, Hormone, and Immunomodulator. Nutrients 2018, 10(11).
12.Wu-Wong JR, Melnick J: Vascular calcification in chronic kidney failure: role of vitamin D receptor. Current opinion in investigational drugs (London, England: 2000) 2007, 8(3):237–247.
13.Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, Komaba H, Ando R, Kakuta T, Fujii H et al: Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2013, 17(3):247–288.
14.Group KDIGOKC-MUW: KDIGO 2017 CLINICAL PRACTICE GUIDELINE UPDATE FOR THE DIAGNOSIS, EVALUATION, PREVENTION, AND TREATMENT OF CHRONIC KIDNEY DISEASE–MINERAL AND BONE DISORDER (CKD-MBD). Kidney Int Supple 2017, 7(1):1–59.
15.John GB, Cheng CY, Kuro-o M: Role of Klotho in aging, phosphate metabolism, and CKD. American journal of kidney diseases: the official journal of the National Kidney Foundation 2011, 58(1):127–134.
16.Melamed ML, Thadhani RI: Vitamin D therapy in chronic kidney disease and end stage renal disease. Clinical journal of the American Society of Nephrology: CJASN 2012, 7(2):358–365.
17.Hishida M, Tamai H, Morinaga T, Maekawa M, Aoki T, Tomida H, Komatsu S, Kamiya T, Maruyama S, Matsuo S et al: Aichi cohort study of the prognosis in patients newly initiated into dialysis (AICOPP): baseline characteristics and trends observed in diabetic nephropathy. Clinical and experimental nephrology 2016, 20(5):795–807.
18.Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone marrow transplantation 2013, 48(3):452–458.
19.Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D, Cannata-Andia JB: Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney international 2008, 74(8):1070–1078.
20.Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA, Jr., Thadhani R: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. Journal of the American Society of Nephrology: JASN 2005, 16(4):1115–1125.
21.Grubler MR, Gaksch M, Kienreich K, Verheyen N, Schmid J, BW OH, Richtig G, Scharnagl H, Meinitzer A, Pieske B et al: Effects of Vitamin D Supplementation on Plasma Aldosterone and Renin-A Randomized Placebo-Controlled Trial. Journal of clinical hypertension (Greenwich, Conn) 2016, 18(7):608–613.
22.Li YC: Discovery of vitamin D hormone as a negative regulator of the renin-angiotensin system. Clinical chemistry 2014, 60(3):561–562.
23.Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C et al: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. Jama 2012, 307(7):674–684.
24.Wang AY, Fang F, Chan J, Wen YY, Qing S, Chan IH, Lo G, Lai KN, Lo WK, Lam CW et al: Effect of paricalcitol on left ventricular mass and function in CKD—the OPERA trial. Journal of the American Society of Nephrology: JASN 2014, 25(1):175–186.
25.Tamez H, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, Pritchett Y, Chang Y, Agarwal R, Wanner C et al: Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. American heart journal 2012, 164(6):902–909.e902.
26.Obi Y, Hamano T, Wada A, Tsubakihara Y: Vitamin D Receptor Activator Use and Cause-specific Death among dialysis Patients: a Nationwide Cohort Study using Coarsened Exact Matching. Scientific reports 2017, 7:41170.
27.Investigators TJ-D: Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis The J-DAVID Randomized Clinical Trial. Jama 2018, 320(December 11):2325 - 2334.
28.Thacher TD, Clarke BL: Vitamin D insufficiency. Mayo Clinic proceedings 2011, 86(1):50–60.
29.Dusso AS: Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation. Kidney international supplements 2011, 1(4):136–141.
30.Gunta SS, Thadhani RI, Mak RH: The effect of vitamin D status on risk factors for cardiovascular disease. Nature reviews Nephrology 2013, 9(6):337–347.
31.Honda H, Koiwa F, Ogata H, Shishido K, Sekiguchi T, Michihata T, Ogawa H, Mukai M, Takahashi K, Suzuki R et al: Active vitamin D analogs, maxacalcitol and alfacalcidol, as maintenance therapy for mild secondary hyperparathyroidism in hemodialysis patients - a randomized study. International journal of clinical pharmacology and therapeutics 2014, 52(5):360–368.
32.Akizawa T, Akiba T, Hirakata H, Kinugasa E, Tominaga Y, Fukagawa M, Yokoyama K, Zhang W, Linde PG, Suzuki M: Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism. Therapeutic apheresis and dialysis: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2015, 19(3):225–234.